Status: Finalised
First registered on:
15/04/2014
Last updated on:
16/04/2014
1. Study identification
EU PAS Register NumberEUPAS6352
Official titleModified Prescription-Event Monitoring Study to Monitor the Introduction of Atrovent Inhaler CFC-Free® MDI in the United Kingdom
Study title acronymAtrovent CFC-free M-PEM
Study typeObservational study
Brief description of the studyThis was a modified prescription event monitoring (M-PEM) study to monitor the safety of Atrovent® CFC-free MDI following a switch from CFC-containing propellants. M-PEM is a non-interventional prospective observational study methodology. The exposure data comprise information from prescriptions collected by the NHS Business Services Authority (NHSBSA) in England. The outcome data are event reports during three month pre- and post-exposure periods, obtained by sending questionnaires to the general practitioners (GPs) who issued prescriptions for Atrovent® CFC-free MDI.
Was this study requested by a regulator?Yes: United Kingdom
Is the study required by a Risk Management Plan (RMP)?
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsDSRU
Department/Research group
Organisation/affiliationDrug Safety Research Unit
Details of (Primary) lead investigator
Title Professor
Last name Shakir
First name Saad
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed05/05/2004
Start date of data collection06/05/2004
Start date of data analysis
Date of interim report, if expected
Date of final study report06/07/2010
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesBoehringer Ingelheim100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Shakir
First name Saad
Address line 1DSRU
Address line 2Bursledon Hall
Address line 3Blundell Lane
CitySouthampton
PostcodeSO31 1AA
CountryUnited Kingdom
Phone number (incl. country code)44-2380-408600
Alternative phone number
Fax number (incl. country code)44-2380-408609
Public Enquiries
Title Professor
Last name Shakir
First name Saad
Address line 1DSRU
Address line 2Bursledon Hall
Address line 3Blundell Lane
CitySouthampton
PostcodeSO31 1AA
CountryUnited Kingdom
Phone number (incl. country code)44-2380-408600
Alternative phone number
Fax number (incl. country code)44-2380-408609
6. Study drug(s) information
Product NameAtrovent CFC-free MDI
CountryUnited Kingdom
Substance INN(s)IPRATROPIUM BROMIDE
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects13211
Additional information
There is only one treatment group: patients prescribed Atrovent CFC-free MDI by their GPs.
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Prescription event monitoring
11. Scope of the study
What is the scope of the study?
Safety
Primary scope : Safety
12. Main objective(s)
What is the main objective of the study?
To actively monitor the safety of the introduction of Atrovent® CFC-free MDI into general practice in England, for both adults and children.
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Prescription event monitoring
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Further information regarding serious suspected ADRs, events of interest, pregnancies, and causes of death, is requested via Follow-Up questionnaires sent to the prescribing GPs. There is no set duration of follow up.
15. Data analysis plan
Please provide a brief summary of the analysis method
Incidence densities for events occurring three months prior to and in the first three months of exposure to Atrovent® CFC-Free MDI were calculated, together with incidence density ratios to compare event rates before and during exposure. A matched analysis of specific events
occurring in the three-month before and three-month after exposure period was performed to produce risk ratios.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
